122 related articles for article (PubMed ID: 11772452)
21. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
[TBL] [Abstract][Full Text] [Related]
22. Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.
Sivak L; Subr V; Tomala J; Rihova B; Strohalm J; Etrych T; Kovar M
Biomaterials; 2017 Jan; 115():65-80. PubMed ID: 27886555
[TBL] [Abstract][Full Text] [Related]
23. Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy.
Zamai M; VandeVen M; Farao M; Gratton E; Ghiglieri A; Castelli MG; Fontana E; D'Argy R; Fiorino A; Pesenti E; Suarato A; Caiolfa VR
Mol Cancer Ther; 2003 Jan; 2(1):29-40. PubMed ID: 12533670
[TBL] [Abstract][Full Text] [Related]
24. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility.
Ríhová B; Srogl J; Jelínková M; Hovorka O; Buresová M; Subr V; Ulbrich K
Ann N Y Acad Sci; 1997 Dec; 831():57-71. PubMed ID: 9616702
[TBL] [Abstract][Full Text] [Related]
25. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
Etrych T; Jelínková M; Ríhová B; Ulbrich K
J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
[TBL] [Abstract][Full Text] [Related]
26. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
27. Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance.
Heinrich AK; Lucas H; Schindler L; Chytil P; Etrych T; Mäder K; Mueller T
Mol Cancer Ther; 2016 May; 15(5):998-1007. PubMed ID: 26939698
[TBL] [Abstract][Full Text] [Related]
28. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice.
Sirova M; Strohalm J; Subr V; Plocova D; Rossmann P; Mrkvan T; Ulbrich K; Rihova B
Cancer Immunol Immunother; 2007 Jan; 56(1):35-47. PubMed ID: 16636810
[TBL] [Abstract][Full Text] [Related]
29. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
30. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.
Omelyanenko V; Gentry C; Kopecková P; Kopecek J
Int J Cancer; 1998 Feb; 75(4):600-8. PubMed ID: 9466663
[TBL] [Abstract][Full Text] [Related]
31. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts.
Shiah JJ; Sun Y; Peterson CM; Kopecek J
J Control Release; 1999 Aug; 61(1-2):145-57. PubMed ID: 10469911
[TBL] [Abstract][Full Text] [Related]
32. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
[TBL] [Abstract][Full Text] [Related]
33. Fine needle aspiration biopsy proves increased T-lymphocyte proliferation in tumor and decreased metastatic infiltration after treatment with doxorubicin bound to PHPMA copolymer carrier.
Betka J; Hovorka O; Boucek J; Ulbrich K; Etrych T; Rihova B
J Drug Target; 2013 Aug; 21(7):648-61. PubMed ID: 23621109
[TBL] [Abstract][Full Text] [Related]
34. HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy.
St'astný M; Plocová D; Etrych T; Kovár M; Ulbrich K; Ríhová B
J Control Release; 2002 May; 81(1-2):101-11. PubMed ID: 11992683
[TBL] [Abstract][Full Text] [Related]
35. Polymer donors of nitric oxide improve the treatment of experimental solid tumours with nanosized polymer therapeutics.
Šírová M; Horková V; Etrych T; Chytil P; Říhová B; Studenovský M
J Drug Target; 2017; 25(9-10):796-808. PubMed ID: 28726521
[TBL] [Abstract][Full Text] [Related]
36. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
[TBL] [Abstract][Full Text] [Related]
37. HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
Sirova M; Kabesova M; Kovar L; Etrych T; Strohalm J; Ulbrich K; Rihova B
Curr Med Chem; 2013; 20(38):4815-26. PubMed ID: 24083609
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity.
Tomala J; Chmelova H; Strohalm J; Ulbrich K; Sirova M; Rihova B; Kovar M
Int J Cancer; 2011 Oct; 129(8):2002-12. PubMed ID: 21165950
[TBL] [Abstract][Full Text] [Related]
39. Poly(2-ethyl-2-oxazoline) conjugates with doxorubicin for cancer therapy: In vitro and in vivo evaluation and direct comparison to poly[N-(2-hydroxypropyl)methacrylamide] analogues.
Sedlacek O; Monnery BD; Mattova J; Kucka J; Panek J; Janouskova O; Hocherl A; Verbraeken B; Vergaelen M; Zadinova M; Hoogenboom R; Hruby M
Biomaterials; 2017 Nov; 146():1-12. PubMed ID: 28892751
[TBL] [Abstract][Full Text] [Related]
40. Reduction-responsive disassemblable core-cross-linked micelles based on poly(ethylene glycol)-b-poly(N-2-hydroxypropyl methacrylamide)-lipoic acid conjugates for triggered intracellular anticancer drug release.
Wei R; Cheng L; Zheng M; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2012 Aug; 13(8):2429-38. PubMed ID: 22746534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
